ClariVest Asset Management’s Cullinan Oncology CGEM Stock Holding History

ClariVest Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$453	Hold	26	–	–	﹤0.01%	793
2024 Q2	$453	Sell	26 -60	-70%	-$1.28K	﹤0.01%	793
2024 Q1	$1.47K	Buy	86 +32	+59%	+$494	﹤0.01%	615
2023 Q4	$550	Hold	54	–	–	﹤0.01%	804
2023 Q3	$0	Hold	54	–	–	﹤0.01%	767
2023 Q2	$1K	Hold	54	–	–	﹤0.01%	585
2023 Q1	$1K	Hold	54	–	–	﹤0.01%	624
2022 Q4	$1K	Buy	54 +25	+86%	+$304	﹤0.01%	600
2022 Q3	$0	Hold	29	–	–	﹤0.01%	693
2022 Q2	$0	Sell	29 -30	-51%	-$340	﹤0.01%	695
2022 Q1	$0	Hold	59	–	–	﹤0.01%	733
2021 Q4	$0	Hold	59	–	–	﹤0.01%	759
2021 Q3	$2K	Hold	59	–	–	﹤0.01%	620
2021 Q2	$2K	Buy	+59	New	+$1.81K	﹤0.01%	608

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ClariVest Asset Management's CGEM Position: Q3 2024 in Review

ClariVest Asset Management held its Cullinan Oncology (CGEM) position steady in Q3 2024 at 26 shares worth $453. The position accounts for ﹤0.01% of the portfolio, ranked #793.

ClariVest Asset Management first reported a position in CGEM in Q2 2021 and has held it in 14 quarters since. The position peaked at $2K in Q3 2021. 137 funds tracked by Wall St. Rank hold CGEM as of Q3 2024.

ClariVest Asset Management held 26 shares of Cullinan Oncology worth $453 as of Q3 2024.
ClariVest Asset Management left its Cullinan Oncology share count unchanged in Q3 2024.
Cullinan Oncology made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #793 holding.
ClariVest Asset Management first reported a position in Cullinan Oncology in Q2 2021 and has held it in 14 quarters since.
ClariVest Asset Management's Cullinan Oncology position peaked at $2K in Q3 2021.
137 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.